Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Accumulated Expenses (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Accumulated Expenses for 5 consecutive years, with $108.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 178.81% year-over-year to $108.3 million, compared with a TTM value of $108.3 million through Sep 2025, up 178.81%, and an annual FY2025 reading of $114.3 million, down 4.29% over the prior year.
  • Accumulated Expenses was $108.3 million for Q3 2025 at Roivant Sciences, up from $88.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $167.1 million in Q1 2023 and bottomed at $38.8 million in Q3 2024.
  • Average Accumulated Expenses over 5 years is $98.9 million, with a median of $106.2 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses tumbled 42.47% in 2022, then skyrocketed 277.59% in 2023.
  • Year by year, Accumulated Expenses stood at $104.1 million in 2021, then rose by 5.04% to $109.4 million in 2022, then decreased by 29.68% to $76.9 million in 2023, then tumbled by 49.48% to $38.8 million in 2024, then soared by 178.81% to $108.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for ROIV at $108.3 million in Q3 2025, $88.7 million in Q2 2025, and $114.3 million in Q1 2025.